- Home
- IGMS vs ADPT Comparison
IGMS vs ADPT Comparison
Compare IGMS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ADPT
- Stock Information
- Founded
- IGMS 1993
- ADPT 2009
- Country
- IGMS United States
- ADPT United States
- Employees
- IGMS N/A
- ADPT N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGMS Health Care
- ADPT Health Care
- Exchange
- IGMS Nasdaq
- ADPT Nasdaq
- Market Cap
- IGMS 729.6M
- ADPT 685.7M
- IPO Year
- IGMS 2019
- ADPT 2019
- Fundamental
- Price
- IGMS $16.03
- ADPT $4.64
- Analyst Decision
- IGMS Hold
- ADPT Buy
- Analyst Count
- IGMS 8
- ADPT 5
- Target Price
- IGMS $14.00
- ADPT $7.00
- AVG Volume (30 Days)
- IGMS 370.4K
- ADPT 1.2M
- Earning Date
- IGMS 11-11-2024
- ADPT 11-07-2024
- Dividend Yield
- IGMS N/A
- ADPT N/A
- EPS Growth
- IGMS N/A
- ADPT N/A
- EPS
- IGMS N/A
- ADPT N/A
- Revenue
- IGMS $2,911,000.00
- ADPT $168,766,000.00
- Revenue This Year
- IGMS $298.54
- ADPT $3.47
- Revenue Next Year
- IGMS $5.74
- ADPT $20.01
- P/E Ratio
- IGMS N/A
- ADPT N/A
- Revenue Growth
- IGMS 74.00
- ADPT N/A
- 52 Week Low
- IGMS $3.81
- ADPT $2.28
- 52 Week High
- IGMS $22.50
- ADPT $5.80
- Technical
- Relative Strength Index (RSI)
- IGMS 55.90
- ADPT 45.13
- Support Level
- IGMS $13.83
- ADPT $4.73
- Resistance Level
- IGMS $17.85
- ADPT $5.13
- Average True Range (ATR)
- IGMS 2.00
- ADPT 0.32
- MACD
- IGMS -0.14
- ADPT -0.06
- Stochastic Oscillator
- IGMS 66.81
- ADPT 3.35
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).